Consolidation therapy with high-dose cyclophosphamide (HDC) reduces minimal residual disease in patients with chronic lymphocytic leukemia (CLL) treated with fludarabine as induction therapy.

被引：0
|
作者：
Weiss, M [1 ]
Glenn, M [1 ]
Maslak, P [1 ]
Rahman, Z [1 ]
Megherian, L [1 ]
Noy, A [1 ]
Zelenetz, A [1 ]
Scheinberg, D [1 ]
Golde, D [1 ]
机构：
[1] MEM SLOAN KETTERING CANC CTR,DIV HEMATOL ONCOL,NEW YORK,NY 10021
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1911 / 1911
页数：1
相关论文
共 50 条
  • [31] Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy.
    Davids, Matthew Steven
    Huang, Ying
    Rogers, Kerry Anne
    Stern, Robert
    Brown, Jennifer R.
    Thompson, Philip A.
    Brander, Danielle M.
    Danilov, Alexey Valeryevich
    Ujjani, Chaitra Shankar
    Parikh, Sameer Ashok
    Barrientos, Jacqueline Claudia
    Tam, Constantine
    Woyach, Jennifer Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
    Eichhorst, BF
    Busch, R
    Hopfinger, G
    Pasold, R
    Hensel, M
    Steinbrecher, C
    Siehl, S
    Jäger, U
    Bergmann, M
    Stilgenbauer, S
    Schweighofer, C
    Wendtner, CM
    Döhner, H
    Brittinger, G
    Emmerich, B
    Hallek, M
    BLOOD, 2006, 107 (03) : 885 - 891
  • [33] Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia
    Dartigeas, Caroline
    Van Den Neste, Eric
    Berthou, Christian
    Maisonneuve, Herve
    Lepretre, Stephane
    Dilhuydy, Marie-Sarah
    Bene, Marie-Christine
    Nguyen-Khac, Florence
    Letestu, Remi
    Cymbalista, Florence
    De Guibert, Sophie
    Aurran, Therese
    Laribi, Kamel
    Vilque, Jean-Pierre
    Tournilhac, Olivier
    Delmer, Alain
    Feugier, Pierre
    Cazin, Bruno
    Michallet, Anne-Sophie
    Levy, Vincent
    Troussard, Xavier
    Delepine, Roselyne
    Tavernier, Elsa
    Colombat, Philippe
    Leblond, Veronique
    LEUKEMIA & LYMPHOMA, 2016, 57 (02) : 328 - 334
  • [34] Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy
    Marotta, G
    Bigazzi, C
    Lenoci, M
    Tozzi, M
    Bocchia, M
    Lauria, F
    HAEMATOLOGICA, 2000, 85 (12) : 1268 - 1270
  • [35] High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy
    Dungarwalla, Moez
    Evans, Steve O.
    Riley, Unell
    Catovsky, Daniel
    Dearden, Clare E.
    Matutes, Estella
    HAEMATOLOGICA, 2008, 93 (03) : 475 - 476
  • [36] Update of experience with fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline therapy for chronic lymphocytic leukemia (CLL)
    Faderl, Stefan
    Wierda, William
    Ferrajoli, Alessandra
    O'Brien, Susan
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Showalter, Brandi L.
    Lerner, Susan
    Keating, Michael J.
    BLOOD, 2007, 110 (11) : 193A - 194A
  • [37] Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group
    Cramer, Paula
    Fink, Anna-Maria
    Busch, Raymonde
    Eichhorst, Barbara
    Wendtner, Clemens-Martin
    Pflug, Natali
    Langerbeins, Petra
    Bahlo, Jasmin
    Goede, Valentin
    Schubert, Friederike
    Doehner, Hartmut
    Stilgenbauer, Stephan
    Dreger, Peter
    Kneba, Michael
    Boettcher, Sebastian
    Mayer, Jiri
    Hallek, Michael
    Fischer, Kirsten
    LEUKEMIA & LYMPHOMA, 2013, 54 (08) : 1821 - 1822
  • [38] Early clinical and pharmacokinetic results of lower dose fludarabine and cyclophosphamide, and high dose rituximab (FCR-Lite) for patients with untreated chronic lymphocytic leukemia (CLL).
    Tarhini, Ahmad A.
    Land, S.
    Meisner, D.
    Pietragallo, L.
    Sulecki, M.
    Lim, F.
    Kiefer, Gauri J.
    Pinkerton, R.
    Obsom, J.
    Sukaly, S.
    Schaefer, P. M.
    Foon, Kenneth A.
    BLOOD, 2006, 108 (11) : 805A - 805A
  • [39] Therapy with fludarabine, cyclophosphamide and rituximab (FCR) for relapsed or untreated progressive chronic lymphocytic leukemia (CLL). A single center experience.
    Pavlovsky, Carolina
    Pavlovsky, Ntiago
    Pardo, Maria L.
    Sapia, Sandra
    Monreal, Maricla
    Corrado, Claudia
    Pavlovsky, Miguel A.
    Fernandez, Isolda
    Juni, Mariana
    BLOOD, 2006, 108 (11) : 329B - 329B
  • [40] Alemtuzumab as consolidation after a response to fludarabine is effective to purge residual disease in patients with chronic lymphocytic leukemia.
    Montillo, M
    Tedeschi, A
    Rossi, V
    Cafro, AM
    Cairoli, R
    Veronese, S
    Scarpati, B
    Farioli, R
    Regazzi, M
    Gambacorta, M
    Morra, E
    BLOOD, 2004, 104 (11) : 140A - 140A
12345